BridgeBio Oncology Therapeutics Inc. (BBOT) Expected Move

Expected move estimates the probable price range for a given period based on at-the-money options pricing. It reflects the market consensus for volatility over the selected timeframe.

BridgeBio Oncology Therapeutics Inc. (BBOT) operates in the Healthcare sector, specifically the Biotechnology industry, with a market capitalization near $718.6M, listed on NASDAQ, employing roughly 62 people, carrying a beta of 0.22 to the broader market. BridgeBio Oncology Therapeutics is a clinical-stage biopharmaceutical company developing next-generation small molecule therapeutics targeting RAS and PI3Kα malignancies, which are prevalent oncogenes in human tumors. Led by Eli Wallace, public since 2025-08-12.

Expected move analysis estimates the probable price range implied by options pricing. No recent options activity for BBOT as of 2026-06-02; this typically reflects low options liquidity, a recently listed name, or a temporary data feed delay. Snapshot will refresh on the next active session.

Learn how expected move is reported and how to read the data →